Loading...
Loading...
ABVC| Name | Value |
|---|---|
| Revenues | 2.2K |
| Cost of Revenue | 146.8K |
| Gross Profit | -144.6K |
| Operating Expense | 1,817.0K |
| Operating I/L | -1,961.6K |
| Other Income/Expense | -1,192.8K |
| Interest Income | 37.5K |
| Pretax | -3,154.4K |
| Income Tax Expense | 175.3K |
| Net Income/Loss | -3,110.9K |
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company focused on developing drugs and medical devices to address unmet medical needs. The company's product pipeline includes ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for pancreatic cancer; ABV-1702 for myelodysplastic syndromes; ABV-1601 for depression in cancer patients; and ABV-1701 Vitargus for retinal detachment or vitreous hemorrhage. ABVC BioPharma, Inc. generates revenue through the development and commercialization of these innovative therapies.
